论文部分内容阅读
宫颈癌是导致全球妇女死亡的主要肿瘤之一。一定型别的人乳头瘤病毒(HPV)感染是宫颈癌发生的必备条件,预防性HPV疫苗可大量减少与此相关的宫颈病变及宫颈癌发病率和死亡率。而由L1自我组装成的病毒样颗粒(VLPs)是预防性疫苗的最佳侯选者之一,肌肉注射VLP后可以产生很强的B细胞、T细胞介导的适应性免疫和中和抗体的天然免疫。VLP的Ⅱ期临床实验均取得可喜成果,Ⅲ期临床实验也在逐步进行。
Cervical cancer is one of the leading causes of death among women worldwide. A certain type of human papillomavirus (HPV) infection is a prerequisite for cervical cancer, preventive HPV vaccine can significantly reduce the incidence of cervical lesions and cervical cancer incidence and mortality. The VLPs assembled by L1 are one of the best candidates for prophylactic vaccines. Muscular injection of VLPs produces strong B cells, T cell-mediated adaptive immunity and neutralizing antibodies Natural immunity. VLP phase Ⅱ clinical trials have achieved gratifying results, phase Ⅲ clinical trials are also gradually carried out.